Precision Biosciences (DTIL) Retained Earnings (2018 - 2026)
Precision Biosciences (DTIL) reported Retained Earnings of -$546.6 million for Q1 2026, down 8.67% year-over-year from -$598.5 million in Q1 2025, and down 3.49% on a QoQ basis from -$528.2 million in Q4 2025.
Precision Biosciences (DTIL) has 9 years of Retained Earnings data on file, last reported at -$546.6 million in Q1 2026.
- Quarterly Retained Earnings fell 8.67% year-over-year to -$546.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$546.6 million (down 8.67% YoY) and the FY2025 annual result came in at -$528.2 million, down 9.48% from the prior year.
- Retained Earnings fell to -$546.6 million in Q1 2026 per DTIL's latest filing, from -$528.2 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$344.8 million in Q1 2022 and bottomed at -$548.3 million in Q3 2025.
- The 5-year median for Retained Earnings is -$473.3 million (2023), against an average of -$468.2 million.
- The widest annual swing landed in 2022, when Retained Earnings sank 35.82%; it then gained 3.65% in 2024.
- Tracing DTIL's Retained Earnings over 5 years: stood at -$428.3 million in 2022, then fell by 14.32% to -$489.6 million in 2023, then grew by 1.46% to -$482.5 million in 2024, then decreased by 9.48% to -$528.2 million in 2025, then declined by 3.49% to -$546.6 million in 2026.
- Per Business Quant, the three latest DTIL Retained Earnings figures stand at -$546.6 million (Q1 2026), -$528.2 million (Q4 2025), and -$548.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - | -546.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -546.63 Mn |
| Dec 31, 2025 | -528.19 Mn |
| Sep 30, 2025 | -548.32 Mn |
| Jun 30, 2025 | -526.55 Mn |
| Mar 31, 2025 | -503.03 Mn |
| Dec 31, 2024 | -482.46 Mn |
| Sep 30, 2024 | -464.72 Mn |
| Jun 30, 2024 | -448.29 Mn |
| Mar 31, 2024 | -481.04 Mn |
| Dec 31, 2023 | -489.63 Mn |
| Sep 30, 2023 | -473.34 Mn |
| Jun 30, 2023 | -465.26 Mn |
| Mar 31, 2023 | -453.37 Mn |
| Dec 31, 2022 | -428.31 Mn |
| Sep 30, 2022 | -399.82 Mn |
| Jun 30, 2022 | -375.88 Mn |
| Mar 31, 2022 | -344.84 Mn |
| Dec 31, 2021 | -316.68 Mn |
| Sep 30, 2021 | -294.39 Mn |
| Jun 30, 2021 | -283.11 Mn |
| Mar 31, 2021 | -304.76 Mn |
| Dec 31, 2020 | -286.07 Mn |
| Sep 30, 2020 | -262.62 Mn |
| Jun 30, 2020 | -236.60 Mn |
| Mar 31, 2020 | -203.90 Mn |
| Dec 31, 2019 | -177.07 Mn |
| Sep 30, 2019 | -156.15 Mn |
| Jun 30, 2019 | -135.41 Mn |
| Mar 31, 2019 | -115.97 Mn |
| Dec 31, 2018 | -85.19 Mn |